ClinicalTrials.gg
Active, not recruitingNCT07681479Updated Sep 10, 2026

A Mass Balance Study of [14C]HRS-9057 for Injection in Healthy Participants

A Phase 1 interventional study of [14C]HRS-9057 in Fluid Retention Due to Heart Failure, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 7 under way, none of them phase 3. Heart Failure · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
10th of 10
6 · median 69
Started
2026
with 3 others
Phase 1
6 of 10
3 open now
Registered
10th of 10
by date

Among the 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd., this one is the 10th largest by enrollment, is one of 4 that started in 2026, is one of 6 in phase 1, and was the 10th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This study is a single-center, open-label, single-dose phase I clinical trial. The trial is divided into four periods: screening, baseline, treatment, and follow-up

03

Conditions studied

  • Fluid Retention Due to Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. was obtained voluntarily
  2. Healthy males aged 18 \~ 45 years (inclusive)
  3. Body weight ≥50 kg, 19 \~ 28 kg/m2 (inclusive)
  4. Adopt efficient measures

Exclusion criteria

Exclusion Criteria:

  1. Have a history of drug allergy, specific allergy, or allergic constitution
  2. Any previous or current medical history that may affect the safety of the participant in the trial or the course of the study drug in vivo
  3. Have a history of risk factors for torsade de pointes
  4. During the screening period, serum potassium, sodium, , or AST were beyond the normal range, or the calculated was less than 90 mL/min/1.73m2
  5. During screening, 12-lead showed atrioventricular block, atrial fibrillation or flutter, ≥450 ms
  6. Chest X-ray findings deemed by the investigator
  7. Have positive test results for surface antigen, virus antibody, or treponema pallidum antibody or nonnegative test result for (HIV) during the screening period
  8. Have used or are using any prescription or over-the-counter drugs within 2 weeks before the dosing
  9. Any drug that inhibits or induces hepatic drug-metabolizing enzymes within 4 weeks prior to administration
  10. All kinds of voiding disorders (such as frequent urination, dysuria, etc.), habitual constipation or diarrhea
  11. Workers engaged in conditions requiring long-term exposure to radioactivity; Or had significant radiation exposure (≥2 chest/abdominal CT scans, or ≥3 other types of X-ray examinations) within 1 year before the trial or had participated in a radiolabeled drug trial within 1 year
  12. Participants may have been unable to complete the study for other reasons or may have been deemed by the investigator to be unsuitable for enrollment
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Dose Level:A

    Subject will receive \[14C\]HRS-9057 at dose level A

    Drug: [14C]HRS-9057

Interventions

06

What researchers measure

Primary outcomes

  1. Total radioactivity recovery and cumulative total radioactivity recovery in urine and feces during each collection period

    Time frame: From Day 1 to Day 28

  2. Percentage of HRS-9057 parent drug and its metabolites in plasma relative to the total radioactivity exposure in plasma (%AUC)

    Time frame: From Day 1 to Day 8

  3. The percentage of HRS-9057 parent drug and its metabolites in urine and feces relative to the administered dose (%Dose)

    Time frame: From Day 1 to Day 28

  4. Pharmacokinetic parameter of total radioactivity in whole blood and plasma, including: Tmax

    Time frame: From Day 1 to Day 28

  5. Pharmacokinetic parameter of total radioactivity in whole blood and plasma, including: Cmax

    Time frame: From Day 1 to Day 28

  6. Pharmacokinetic parameter of total radioactivity in whole blood and plasma, including: t1/2

    Time frame: From Day 1 to Day 28

  7. Pharmacokinetic parameter of total radioactivity in whole blood and plasma, including: MRT

    Time frame: From Day 1 to Day 28

  8. Pharmacokinetic parameter of total radioactivity in whole blood and plasma, including: AUC

    Time frame: From Day 1 to Day 28

Secondary outcomes

  1. Pharmacokinetic parameter of HRS-9057, and other major metabolites (if applicable) in plasma, including: Tmax

    Time frame: From Day 1 to Day 28

  2. Pharmacokinetic parameter of HRS-9057, and other major metabolites (if applicable) in plasma, including: Cmax

    Time frame: From Day 1 to Day 28

  3. Pharmacokinetic parameter of HRS-9057, and other major metabolites (if applicable) in plasma, including: t1/2

    Time frame: From Day 1 to Day 28

  4. Pharmacokinetic parameter of HRS-9057, and other major metabolites (if applicable) in plasma, including: MRT

    Time frame: From Day 1 to Day 28

  5. Pharmacokinetic parameter of HRS-9057, and other major metabolites (if applicable) in plasma, including: AUC

    Time frame: From Day 1 to Day 28

  6. Serious adverse events

    Time frame: From ICF signing date to Day 28

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2026 to primary completion in Aug 2026, 0 months.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 0 months is below that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jul 2, 2026
StartActual
Aug 11, 2026
Primary completionActual
Aug 11, 2026
CompletionEst.
Dec 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07681479
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Aug 11, 2026
Primary completion
Aug 11, 2026
Completion
Dec 2026 (estimated)
Last update
Sep 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-9057

Start the discussion